TTrialPathMatch Me to Trials
← Back to trials
RecruitingPrimary Biliary Cholangitis

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

Eligible age

18–75 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.

Sponsor: Gilead Sciences

Where it's recruiting

Colorado

Colorado Springs

Florida

Lakewood Rch

Georgia

Atlanta

Tennessee

Johnson City

Source: ClinicalTrials.gov · NCT07841977 · last updated 2026-10-27

Study of Seladelpar and Cilofexor in Participants With Primary Biliary · TrialPath